Pharmaceuticals & Biotechnology

REVIVA PHARMACEUTICALS HOLDINGS, INC. CEO pay

Narayan Prabhu, Chief Executive Officer and President. Fiscal year 2024, as reported to the SEC.

Total compensation

$405K

$404,950 for fiscal 2024: the Summary Compensation Table total, with stock and option awards at their grant-date value.

Definitive proxy statement, filed 2025-11-04SEC accession number 0001437749-25-033023

In context

The median chief executive among 465 Pharmaceuticals & Biotechnology companies was paid $2.2M. The middle half ranged from $1M to $4.9M.

Narayan Prabhu's total is below that median.

See how your pay compares to REVIVA PHARMACEUTICALS HOLDINGS, INC.'s peers

CEOSalary breaks this total into salary, bonus, stock and option awards, builds a peer set of comparable companies around it, and places your own package against them, with every figure cited to its filing.

Start a 3-day trial

Source: REVIVA PHARMACEUTICALS HOLDINGS, INC.'s definitive proxy statement (SEC Form DEF 14A), Summary Compensation Table, fiscal year 2024. Figures are as reported by the company and are not adjusted or estimated. Context figures are from CEOSalary's snapshot of SEC filings as of 2026-10-28. Not financial, legal or compensation-consulting advice.